We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc (“GWPH” or the “Company”) (NASDAQ: GWPH) in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals Public Limited Company (“Jazz”) (NASDAQ: JAZZ).  Under the terms of the merger agreement, Jazz will acquire GWPH in a mixed cash-and-stock transaction for $220.00 per American Depositary Share (“ADS”), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares.  The proposed transaction is valued at approximately $7.2 billion.

WeissLaw LLP is investigating whether GWPH’s board acted in the best interest of GWPH’s public shareholders in agreeing to the proposed transaction, whether the merger consideration adequately compensates GWPH’s shareholders, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to GWPH’s public shareholders. WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com